Effect of age and frailty on the efficacy and tolerability of once-weekly selinexor, bortezomib, and dexamethasone in previously treated multiple myeloma
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F61988987%3A17110%2F21%3AA2202CTD" target="_blank" >RIV/61988987:17110/21:A2202CTD - isvavai.cz</a>
Alternative codes found
RIV/00843989:_____/21:E0109006 RIV/00216208:11110/21:10438210 RIV/65269705:_____/21:00074360 RIV/00064165:_____/21:10438210
Result on the web
<a href="https://www.webofscience.com/wos/woscc/full-record/WOS:000646325700001?SID=D1v41LNKnqSuWlaZyU6" target="_blank" >https://www.webofscience.com/wos/woscc/full-record/WOS:000646325700001?SID=D1v41LNKnqSuWlaZyU6</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1002/ajh.26172" target="_blank" >10.1002/ajh.26172</a>
Alternative languages
Result language
angličtina
Original language name
Effect of age and frailty on the efficacy and tolerability of once-weekly selinexor, bortezomib, and dexamethasone in previously treated multiple myeloma
Original language description
Elderly and frail patients with multiple myeloma (MM) are more vulnerable to the toxicity of combination therapies, often resulting in treatment modifications and suboptimal outcomes. The phase 3 BOSTON study showed that once-weekly selinexor and bortezomib with low-dose dexamethasone (XVd) improved PFS and ORR compared with standard twice-weekly bortezomib and moderate-dose dexamethasone (Vd) in patients with previously treated MM. This is a retrospective subgroup analysis of the multicenter, prospective, randomized BOSTON trial. Post hoc analyses were performed to compare XVd versus Vd safety and efficacy according to age and frailty status (<65 and >= 65 years, nonfrail and frail). Patients >= 65 years with XVd had higher ORR (OR 1.77, p = .024), >= VGPR (OR, 1.68, p = .027), PFS (HR 0.55, p = .002), and improved OS (HR 0.63, p = .030), compared with Vd. In frail patients, XVd was associated with a trend towards better PFS (HR 0.69, p = .08) and OS (HR 0.62, p = .062). Significant improvements were also observed in patients <65 (ORR and TTNT) and nonfrail patients (PFS, ORR, >= VGPR, and TTNT). Patients treated with XVd had a lower incidence of grade >= 2 peripheral neuropathy in >= 65 year-old (22% vs. 37%; p = .0060) and frail patients (15% vs. 44%; p = .0002). Grade >= 3 TEAEs were not observed more often in older compared to younger patients, nor in frail compared to nonfrail patients. XVd is safe and effective in patients <65 and >= 65 and in nonfrail and frail patients with previously treated MM.
Czech name
—
Czech description
—
Classification
Type
J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database
CEP classification
—
OECD FORD branch
30205 - Hematology
Result continuities
Project
—
Continuities
V - Vyzkumna aktivita podporovana z jinych verejnych zdroju
Others
Publication year
2021
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
American Journal of Hematology
ISSN
0361-8609
e-ISSN
—
Volume of the periodical
96
Issue of the periodical within the volume
6
Country of publishing house
US - UNITED STATES
Number of pages
11
Pages from-to
708-718
UT code for WoS article
000646325700001
EID of the result in the Scopus database
—